ALK and anaplastic large cell lymphoma: The sixth Forum, again on ALK inhibitors, concluded that there were more clinical trials and regulatory submissions since the first Forum, ALK inhibitors should be included in front-line therapy of anaplastic large cell lymphoma (ALCL), the efficacy and safety of lorlatinib needed to be determined in front-line therapy in patients with neuroblastoma, and ALK inhibitors with very good central nervous system (CNS) penetration should be evaluated in CNS tumors with ALK fusions (13).